The DOI matches its Crossref record.
Cycling to Cancer with Cyclin D1
Open accessAbstract
Genetic aberrations in the regulatory circuits that govern transit through the G(1) phase of the cell cycle occur frequently in human cancer and overexpression of the G(1) phase cyclin, cyclin D1, is one of the most commonly observed alterations. Cyclin D1 accumulates and activates its cognate CDK (CDK4/6) in response to mitogenic growth factors in early to mid G(1) phase. The resulting cyclin D1-dependent kinase initiates the phosphorylation-dependent inactivation of the retinoblastoma tumor suppressor protein. Mitogen-dependent activation of the cyclin D1 kinase occurs through increased transcription, protein accumulation, cyclin/CDK assembly, reduced cyclin proteolysis, and decreased nuclear export. Perturbations at any step, which result in reduced growth factor requirements for cyclin D1/CDK activation, will provide cells with a distinct growth advantage over their normal counterparts and thus likely represents an early event in neoplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Molecular targets of dietary agents for prevention and therapy of cancer
Aggarwal, B. B., & Shishodia, S. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.009 · Cited by 1,754
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., Sun, Z., & Zheng, X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.03.057 · Cited by 514
The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine
Qi, P., & Du, X. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.160 · Cited by 506
Large non-coding RNAs: missing links in cancer?
Huarte, M., & Rinn, J. L. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq353 · Cited by 484
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Role of Curcumin in Cancer Therapy
Shishodia, S., Chaturvedi, M. M., & Aggarwal, B. B. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.04.001 · Cited by 413
Pan, L., Feng, F., Wu, J., Fan, S., Han, J., Wang, S., Yang, L., Liu, W., Wang, C., & Xu, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106270 · Cited by 383
Anti cancer effects of curcumin: cycle of life and death
Sa, G., & Das, T. (2008) · Cell Division · doi:10.1186/1747-1028-3-14 · Cited by 382
Discovery of multi-dimensional modules by integrative analysis of cancer genomic data
Zhang, S., Liu, C.-C., Li, W., Shen, H., Laird, P. W., & Zhou, X. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks725 · Cited by 374
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Self-citationMolecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Ahmed, S., Sulaiman, S. A., Baig, A. A., Ibrahim, M., Liaqat, S., Fatima, S., Jabeen, S., Shamim, N., & Othman, N. H. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8367846 · Cited by 352
Hauptman, N., & Glavač, D. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14034655 · Cited by 349
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Versatility of PRMT5-induced methylation in growth control and development
Karkhanis, V., Hu, Y.-J., Baiocchi, R. A., Imbalzano, A. N., & Sif, S. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.09.001 · Cited by 280
Molecular mechanisms of curcumin action: Gene expression
Shishodia, S. (2013) · BioFactors · doi:10.1002/biof.1041 · Cited by 263
Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells
Almeida, M. I., Nicoloso, M. S., Zeng, L., Ivan, C., Spizzo, R., Gafà, R., Xiao, L., Zhang, X., Vannini, I., Fanini, F., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.047 · Cited by 202
EWS–ETS oncoproteins: The linchpins of Ewing tumors
Janknecht, R. (2005) · Gene · doi:10.1016/j.gene.2005.08.007 · Cited by 173
Barbash, O., Zamfirova, P., Lin, D. I., Chen, X., Yang, K., Nakagawa, H., Lu, F., Rustgi, A. K., & Diehl, J. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.017 · Cited by 140
Self-citationHsc70 regulates accumulation of cyclin D1 and cyclin D1-dependent protein kinase
Diehl, J. A., Yang, W., Rimerman, R. A., Xiao, H., & Emili, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1764-1774.2003 · Cited by 97
Park, G. H., Song, H. M., & Jeong, J. B. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.07.008 · Cited by 35
Xiang, Y., Yang, Y., Lin, C., Wu, J., & Zhang, X. (2020) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-020-00726-4 · Cited by 26
Metadata
- Authors
- Diehl, J. A.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2002-05-05
- Volume
- 1
- Issue
- 3
- Pages
- 226-231
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2102942479
- Cited by
- 475
- References
- 0
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.